Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis
2023 · ESMO Open · 70 citations
https://doi.org/10.1016/j.esmoop.2023.101592
F
Flavia Jacobs
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
72
Papers
631
Citations
15
h-index
23
i10-index
Flavia Jacobs is an academic researcher from Humanitas University. The author has contributed to research in topics: Advanced Breast Cancer Therapies & Breast Cancer Treatment Studies & Cancer Treatment and Pharmacology. The author has an h-index of 15, co-authored 62 publications.
ORCID: 0000-0001-9126-8325Papers by this author
worksCyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions
2024 · Critical Reviews in Oncology/Hematology · 60 citations
https://doi.org/10.1016/j.critrevonc.2024.104324
Opportunities and Challenges of Synthetic Data Generation in Oncology
2023 · JCO Clinical Cancer Informatics · 35 citations
https://doi.org/10.1200/cci.23.00045
Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study
2025 · Annals of Oncology · 26 citations
https://doi.org/10.1016/j.annonc.2025.03.023
Hope and Hype around Immunotherapy in Triple-Negative Breast Cancer
2023 · Cancers · 20 citations
https://doi.org/10.3390/cancers15112933
HR+/HER2– de novo metastatic breast cancer: a true peculiar entity?
2023 · Drugs in Context · 17 citations
https://doi.org/10.7573/dic.2022-12-2
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat